Pfizer Inc. has acquired exclusive rights to commercialize an obesity therapy in China, strengthening its push into the ...
Amid obesity push, Pfizer strikes deal worth up to $495M to market Sciwind's approved GLP-1 in China
More recently, Pfizer splashed out $150 million upfront—and put up hundreds of millions more in potential milestones—to acquire worldwide rights to a GLP-1 agonist dubbed YP05002 from Yao Pharma, a ...
Pfizer has entered an agreement to license Sciwind Biosciences' type 2 diabetes treatment ecnoglutide, with potential ...
Agreement worth up to $495 million is part of a growing number of Chinese deals with global pharma giants as the country advances from a role as follower to innovator ...
Ecnoglutide is one of a growing number of GLP-1 drugs in Chinese market. Sciwind gained approved for it to be used in China ...
Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.
Sciwind said the agreement marks “an important first step to advance Pfizer's global strategy in the metabolic field in China,” according ...
Pfizer (NYSE:PFE) reported positive topline Phase 3 results from its BREAKWATER oncology trial in metastatic colorectal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results